1 / 3

A Market Space Beyond Lucentis and Eylea for Retinal Vein Occlusion Treatment

The most prevalent cause of vision loss in older people and the second most common retinal vascular disorder to endanger one's ability to see is retinal vein occlusion. Our calculations indicate that there were over 1.2 million diagnosed cases of Retinal Vein Occlusion in the 7MM in 2021, which is projected to rise by 2032.

ffathima
Download Presentation

A Market Space Beyond Lucentis and Eylea for Retinal Vein Occlusion Treatment

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A Market Space Beyond Lucentis and Eylea for Retinal Vein Occlusion Treatment delveinsight2208.blogspot.com/2022/09/a-market-space-beyond-lucentis-and.html What is Retinal Vein Occlusion? The most prevalent cause of vision loss in older people and the second most common retinal vascular disorder to endanger one's ability to see is retinal vein occlusion. Our calculations indicate that there were over 1.2 million diagnosed cases of Retinal Vein Occlusion in the 7MM in 2021, which is projected to rise by 2032. Additionally, in the 7MM, girls outnumbered males in the overall number of diagnosed prevalent cases of Retinal Vein Occlusion (RVO) in the year 2021. By the year 2032, these cases are anticipated to rise, according to estimations. Additionally, it was noted that BRVO cases outnumbered CRVO cases in total diagnosed frequent RVO cases in the US in 2021, and these instances are projected to rise sharply by 2032. Age and systemic vascular problems are major risk factors for RVO, and age is a significant factor in determining the severity of the disease's progression. As a result, the prevalence and awareness of the condition are rising along with the growing elderly population. It typically affects people in their sexagenarian years and older, making diagnosis and treatment challenging because of the related comorbidities, including diabetes and high blood pressure. However, the retinal vein occlusion treatment setting remains just as constrained as it was ten years ago. A curative treatment that reverses retinal vascular occlusion is a critical unmet need, even though there are FDA-approved medications for the indication. The treatments for retinal vein occlusion that are currently available manage the symptom to stop additional vision loss and lessen the harm caused by side effects such as macular edoema, ischemia, or neovascularization. Currently, the FDA has approved three medications: Roche's Lucentis (ranibizumab), Eylea (aflibercept) by Regeneron, which are intravitreal injections of anti-VEGFs, and Ozurdex by AbbVie, which is a dexamethasone implant, to treat macular edoema secondary to branch retinal vein occlusion and central retinal vein occlusion market. Off- label treatments for retinal vein occlusion, such as Roche's Avastin (bevacizumab) and intravitreal triamcinolone, are popular and widely utilized. As the only approved medication in the distinct corticosteroid market with no substantial competitors, Ozurdex injection by AbbVie, a dexamethasone implant with a distinctive mechanism of action, has earned a significant position in the competitive retinal vein occlusion therapy market. This second-line therapy for eyes with persistent edoema that 1/3

  2. do not respond well to anti-VEGF injections has a patent exclusivity period until 2023, so there is little to worry about. Off-label intravitreal triamcinolone, however, enters this restricted area with less impact. Along with these rising stars, there are a few early-stage retinal vein occlusion medications worth mentioning, such as ANXV by Annexin Pharmaceuticals, Autologous Bone Marrow CD34+ Stem Cells by The Emmes Company, and EYP-1901 (vorolanib) by EyePoint Pharmaceuticals. If approved, these medications may offer the much-needed RVO cure. It is still too soon to get overly excited about these medications, but based on our data, they are the ones to keep an eye on in a retinal vein occlusion treatment market that is now dominated by anti-VEGF and corticosteroids. Related Reports: Diagnostic Imaging Equipment Market Diagnostic Imaging Equipment Market By Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, And Others), By Application (Cardiology, Oncology, Gastroenterology, Gynecology, And Other Applications), By End- User (Hospitals, Diagnostic Imaging Centres, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to rising technological advancement and increasing prevalence of chronic diseases. Invasive Candidiasis Market "DelveInsight’s ‘Invasive Candidiasis Market Insight, Competitive Landscape and Market Forecast, 2027’ report delivers an in-depth understanding of Invasive Candidiasis and the historical and forecasted Invasive Candidiasis market trends, globally, which comprises of North America, Europe, APAC, and RoW. Sialidosis Market DelveInsight's "Sialidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology as well as the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Filgrastim Biosimilar Insight DelveInsight’s, “Filgrastim Biosimilar Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including 2/3

  3. clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Pain Management Devices Market Pain Management Devices Market By Type Of Devices (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps [Intrathecal Infusion Pumps and External Infusion Pumps], Ablation Devices [Radiofrequency Ablation Devices And Cryoablation Devices], And Others), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, and Others), By Geography is expected to grow at a steady CAGR Forecast till 2027 Latest Reports by DelveInsight Basal Cell Carcinoma Market | Birch Allergy Market | Bile Duct Neoplasm Market | Gingivitis Market | Lupus Nephritis Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Congestive Heart Failure Market | Gingivitis Market | Lupus Nephritis Market | Erythromelalgia Market | AL Amyloidosis Market | Primordial Dwarfism Market | Breast Pumps Market | Hyperuricemia Market | Helicobacter Pylori (H. pylori) Infection Market | AIDS Dementia- Market | Follicular Lymphoma Market | Chronic Pulmonary Hypertension Market | Adrenal Crisis Market | Retinoblastoma Market | Non-Cystic Fibrosis Bronchiectasis Market | Microsatellite Stable Colorectal Cancer Market | Chondrosarcoma Market | Sialidosis Market To know more about our Competitive Services, Click here: Pharma Competitive Intelligence https://www.delveinsight.com/consulting/competitive-intelligence-services 3/3

More Related